LAURIE KEATING - 01 Jan 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: Director
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Laurie B. Keating
Issuer symbol: IMRX
Transactions as of: 01 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Jan 2026, 16:56:14 UTC
Previous filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
KEATING LAURIE	Director	245 MAIN STREET, SECOND FLOOR, CAMBRIDGE	/s/ Michael D. Bookman, Attorney-in-Fact for Laurie B. Keating	02 Jan 2026	0001620743

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMRX	Stock Option	Award	$0	+7,888		$0.000000	7,888	01 Jan 2026	Class A Common Stock	7,888	$6.58	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).
F2	The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

Content

Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.